DL-TBOA Inhibitor

Name: DL-TBOA Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753023
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753023

DL-TBOA inhibited [14C] glutamate uptake in COS-1 cells expressing human EAAT1 and EAAT2, with Ki values of 42uM and 5.7 uM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner, with Ki values of 4.4uM and 3.2uM, respectively. DL-TBOA is an… More details

DISCONTINUED
Click here to view our similar product(s) OR click here to contact our technical support team for suitable replacement.

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Product Name

DL-TBOA, Inhibitor

Full Product Name

DL-TBOA

Product Gene Name

DL-TBOA, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

239.22

Solubility

<1mg/ml refers to the product slightly soluble or insoluble

Formula

C11H13NO5

SMILES

OC([C@@H](N)[C@@H](C(O)=O)OCC1=CC=CC=C1)=O.[Relative stereochemistry]

CAS Number

205309-81-5

Target & IC50

EAAT1: ic50 70uM
EAAT2: ic50 6uM
EAAT3: ic50 6uM
human EAAT1: ic50 42uM (ki)
human EAAT2: ic50 5.7uM
EAAT4: ic50 4.4uM
EAAT5: ic50 3.2uM

Product Categories/Family for DL-TBOA, inhibitor

Metabolism; transporter

Product References and Citations for DL-TBOA, inhibitor

Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.
Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8.
Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8.
Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.
Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.
Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-beta-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.
Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-beta-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.

Other Notes

Small volumes of DL-TBOA, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for DL-TBOA purchase

MBS5753023 is an inhibitor targeting DL-TBOA.